Skip to main content
Premium Trial:

Request an Annual Quote

C2Sense, Princeton BioMeditech Nab $1.5M in RADx Funding to Develop At-Home COVID-19, Flu Test

NEW YORK — C2Sense and Princeton BioMeditech said on Tuesday that they have received $1.5 million in funding through the US National Institutes of Health's Rapid Acceleration of Diagnostics (RADx) Tech High Performance program to develop an at-home test for COVID-19 and influenza A and B.

With the Phase I funding, the companies aim to adapt Princeton BioMeditech's Status COVID-19/Flu test — a lateral flow immunochromatographic assay that received Emergency Use Authorization from the US Food and Drug Administration in early 2021 — into an over-the-counter fluorescent immunoassay that can run on C2Sense's Halo lateral flow assay reader and companion app.

A C2Sense spokesperson said that the companies could receive an additional $3.2 million in funding if the effort advances into Phase II under the RADx Tech program.

Watertown, Massachusetts-based C2Sense is a spinout of the Massachusetts Institute of Technology. It raised $8 million in Series B funding earlier this year.

Princeton BioMeditech, headquartered in Monmouth Junction, New Jersey, received RADx funding to develop a rapid SARS-CoV-2 test in late 2021.